Polygenic Score (PGS) ID: PGS005312

Predicted Trait
Reported Trait Psoriasis
Mapped Trait(s) psoriasis (EFO_0000676)
Additional Trait Information Score was developed using GWAS of psoriasis susceptibility and tested on prediction of severe psoriasis (vs. non-severe disease)
Released in PGS Catalog: Jan. 19, 2026
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name Full-noHLA_subset
Development Method
Name SBayesR
Parameters SNPs in high LD removed (R2 > 0.9, SNP with lowest susceptibility P-value was retained). Otherwise standard SBayesR arguments. Variants filtered to only those in study datasets (Estonian Biobank, FinnGen, HUNT, UK Biobank, BSTOP, Novartis).
Variants
Original Genome Build hg19
Number of Variants 487,310
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000760
Citation (link to publication) Saklatvala JR et al. Genome Med (2025)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
52,950 individuals (100%)
PGS Evaluation
European: 100%
2 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
—
[
  • 19,842 cases
  • , 33,108 controls
]
 European CASP, Genizon, KIEL, UCSF, WTCCC

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM023032 PSS012093|
European Ancestry|
13,577 individuals
 PGP000760 |
Saklatvala JR et al. Genome Med (2025)
 Reported Trait: Severe psoriasis (BSTOP) vs. any psoriasis (UKB) — — Percentage of cases with risk >95th percentile of UKB psoraisis cases: 15.3 — —
PPM023034 PSS012097|
European Ancestry|
10,887 individuals
 PGP000760 |
Saklatvala JR et al. Genome Med (2025)
 Reported Trait: Severe psoriasis (Novartis) vs. any psoriasis (UKB) — — Percentage of cases with risk >95th percentile of UKB psoraisis cases: 11.5 — —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS012097 — — 1,461 individuals — European — Novartis 1,461 in Novartis is compared against 9426 UKB
PSS012097 — — 9,426 individuals — European — UKB 1,461 in Novartis is compared against 9426 UKB
PSS012093 — — 4,151 individuals — European — BSTOP 4,151 in BSTOP is compared against 9426 UKB
PSS012093 — — 9,426 individuals — European — UKB 4,151 in BSTOP is compared against 9426 UKB